Other languages Nkarta, Inc.

Equities

NKTX

US65487U1088

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-30 EDT			5-day change	1st Jan Change
6.68 ^USD	-3.47%		-11.64%	+1.21%

03-26	Canaccord Genuity Adjusts Nkarta's Price Target to $16 From $15, Keeps Buy Rating	MT
03-25	HC Wainwright Adjusts Price Target on Nkarta to $22 From $20, Keeps Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nkarta Prices $240.1 Million Underwritten Offering	03-25
Nkarta Trims Q4 Loss -- Shares Up After Hours	03-21
Nkarta, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21
Nkarta, Inc. Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition	12-09
Nkarta, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Sector Update: Health Care Stocks Retreat in Late Afternoon	23-10-17
Top Midday Gainers	23-10-17
Sector Update: Health Care Stocks Mixed in Tuesday Afternoon Trading	23-10-17
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis	23-10-17
Nkarta Says FDA Clears IND Application for Lupus Nephritis Treatment; Planning Cost Cuts to Extend Cash Runway	23-10-17
Nkarta Shares Double on Partnership With Lupus Therapeutics for Cell Therapy to Treat Lupus, FDA Application Approval	23-10-17
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis	23-10-17
Nkarta, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Nkarta Names Alyssa Levin as Chief Financial and Business Officer	23-07-05
Nkarta, Inc. Appoints Alyssa Levin as Chief Business Officer	23-07-05
Top Midday Decliners	23-06-28
Nkarta Says Leukemia Drug Showed 'Encouraging' Results in Phase 1 Study	23-06-27
Nkarta, Inc. Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia	23-06-27
Nkarta, Inc. to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma	23-05-11
Nkarta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Nkarta, Inc.

Equities

NKTX

US65487U1088

Other languages

Filters